WO2010017236A1 - Pde10 inhibitors and related compositions and methods - Google Patents

Pde10 inhibitors and related compositions and methods Download PDF

Info

Publication number
WO2010017236A1
WO2010017236A1 PCT/US2009/052754 US2009052754W WO2010017236A1 WO 2010017236 A1 WO2010017236 A1 WO 2010017236A1 US 2009052754 W US2009052754 W US 2009052754W WO 2010017236 A1 WO2010017236 A1 WO 2010017236A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
substituted
disorders
alkyl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/052754
Other languages
English (en)
French (fr)
Inventor
Neil S. Cutshall
Jennifer Lynn Gage
Neil Thomas Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Omeros Corp
Original Assignee
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Medical Systems Inc filed Critical Omeros Medical Systems Inc
Priority to ES09805466.1T priority Critical patent/ES2654617T3/es
Priority to NZ590951A priority patent/NZ590951A/xx
Priority to EP09805466.1A priority patent/EP2310016B1/en
Priority to JP2011522195A priority patent/JP5759893B2/ja
Priority to AU2009279756A priority patent/AU2009279756B2/en
Priority to CA2733378A priority patent/CA2733378C/en
Priority to CN200980134364.6A priority patent/CN102143752B/zh
Publication of WO2010017236A1 publication Critical patent/WO2010017236A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/30—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C07C243/32—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/78—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C07C251/80—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/88—Hydrazones having also the other nitrogen atom doubly-bound to a carbon atom, e.g. azines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/63—Carboxylic acid nitriles containing cyano groups and nitrogen atoms further bound to other hetero atoms, other than oxygen atoms of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C255/65—Carboxylic acid nitriles containing cyano groups and nitrogen atoms further bound to other hetero atoms, other than oxygen atoms of nitro or nitroso groups, bound to the same carbon skeleton with the nitrogen atoms further bound to nitrogen atoms
    • C07C255/66—Carboxylic acid nitriles containing cyano groups and nitrogen atoms further bound to other hetero atoms, other than oxygen atoms of nitro or nitroso groups, bound to the same carbon skeleton with the nitrogen atoms further bound to nitrogen atoms having cyano groups and nitrogen atoms being part of hydrazine or hydrazone groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Definitions

  • This invention relates generally to compounds having activity as PDElO inhibitors, and to compositions containing the same, as well as to methods of treating various disorders by administration of such compounds to a warm-blooded animal in need thereof.
  • Cyclic nucleotide phosphodiesterases are represented by a large superfamily of enzymes. PDEs are known to possess a modular architecture, with a conserved catalytic domain proximal to the carboxyl terminus, and regulatory domains or motifs often near the amino terminus. The PDE superfamily currently includes more than twenty different genes subgrouped into eleven PDE families (Lugnier, C, "Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.” Pharmacol Ther. 2006 Mar; 109(3):366-98).
  • PDElO has the capacity to hydrolyze both cAMP and cGMP; however, the K m for cAMP is approximately 0.05 ⁇ M, whereas the K M for cGMP is 3 ⁇ M. In addition, the Vm 3x for cAMP hydrolysis is fivefold lower than for cGMP. Because of these kinetics, cGMP hydrolysis by PDElO is potently inhibited by cAMP in vitro, suggesting that PDElO may function as a cAMP-inhibited cGMP phosphodiesterase in vivo. Unlike PDE8 or PDE9, PDElO is inhibited by IBMX with an IC 50 (50% inhibitory concentration) of 2.6 ⁇ M. (See Soderling and Beavo, "Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions," Current Opinion in Cell Biology, 2000, 12:174-179.)
  • PDElO contains two amino-terminal domains that are similar to the cGMP-binding domains of PDE2, PDE5 and PDE6, which are domains conserved across a wide variety of proteins. Because of the wide conservation of this domain, it is now referred to as the GAF domain (for the GAF proteins: cGMP binding phosphodiesterases; the cynobacterial Anabaena adenylyl cyclase; and the Escherichia coli transcriptional regulator fhlA). Although in PDE2, PDE5 and PDE6 the GAF domains bind cGMP, this is probably not the primary function of this domain in all cases ⁇ e.g., E. coli are not thought to synthesize cGMP).
  • Inhibitors of the PDE family of enzymes have widely been sought for a broad indication of therapeutic uses.
  • Reported therapeutic uses of PDE inhibitors include allergies, obtrusive lung disease, hypertension, renal carcinoma, angina, congestive heart failure, depression and erectile dysfunction (WO 01/41807 A2).
  • Other inhibitors of PDE have been disclosed for treatment of ischemic heart conditions (U.S. Pat. No. 5,693,652).
  • More specifically, inhibitors of PDElO have been disclosed for treatment of certain neurological and psychiatric disorders including, Parkinson's disease, Huntington's disease, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders (U.S. Patent Application No. 2003/0032579).
  • PDElO has been shown to be present at high levels in neurons in areas of the brain that are closely associated with many neurological and psychiatric disorders. By inhibiting PDElO activity, levels of cAMP and cGMP are increased within neurons, and the ability of these neurons to function properly is thereby improved. Thus, inhibition of PDElO is believed to be useful in the treatment of a wide variety of conditions or disorders that would benefit from increasing levels of cAMP and cGMP within neurons, including those neurological, psychotic, anxiety and/or movement disorders mentioned above.
  • this invention is generally directed to compounds that have activity as PDElO inhibitors, as well as to methods for their preparation and use, and to pharmaceutical compositions containing the same.
  • the compounds have the following general structure (I):
  • the compounds have the following general structure (IV):
  • the compounds of this invention have utility over a wide range of therapeutic applications, and may be used to treat a wide variety of conditions or disorders that would benefit from increasing levels of cAMP and cGMP, especially within neurons, including (but not limited to) neurological disorders, such as psychotic disorders, anxiety disorders, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, bipolar disorders, post-traumatic stress disorders, drug-induced psychosis, panic disorders, obsessive-compulsive disorders, attention-deficit disorders, disruptive behavior disorders, autism, depression, dementia, cognitive disorders, epilepsy, insomnias and multiple sclerosis.
  • neurological disorders such as psychotic disorders, anxiety disorders, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias
  • the methods of this invention include administering an effective amount of a compound of the foregoing structures, typically in the form of a pharmaceutical composition, to a mammal in need thereof, including a human.
  • a pharmaceutical composition containing one or more compounds of the foregoing structures in combination with a pharmaceutically acceptable carrier or diluent.
  • FIGURE 1 illustrates that Compound 12-63 of the present invention (as identified in Table 1 of Example 12) significantly reduces hyperactivity of mice in a psychostimulant (PCP)-induced model of psychosis as compared to vehicle control.
  • PCP psychostimulant
  • FIGURE 2 illustrates that Compound 12-55 of the present invention (as identified in Table 1 of Example 12) significantly reduces hyperactivity of mice in the PCP-induced model of psychosis as compared to vehicle control.
  • FIGURE 3 illustrates that Compound 12-60 of the present invention (as identified in Table 1 of Example 12) significantly reduces hyperactivity of mice in the PCP-induced model of psychosis as compared to vehicle control.
  • FIGURE 4 illustrates that Compound 12-44 of the present invention (as identified in Table 1 of Example 12) significantly reduces a conditioned avoidance response (CAR) in mice trained in a CAR model of psychosis as compared to vehicle control.
  • CAR conditioned avoidance response
  • FIGURES 5 A and 5B illustrate that Compound 12-63 of the present invention (as identified in Table 1 of Example 12) significantly reduces hyperactivity of mice in the PCP-induced model of psychosis as compared to vehicle control (FIGURE
  • FIGURES 6A and 6B illustrate that Compound 12-104 of the present invention (as identified in Table 1 of Example 12) significantly reduces hyperactivity of mice in the PCP-induced model of psychosis as compared to vehicle control (FIGURE
  • FIGURES 7A and 7B illustrate that Compound 12-114 of the present invention (as identified in Table 1 of Example 12) significantly reduces hyperactivity of mice in the PCP-induced model of psychosis as compared to vehicle control (FIGURE
  • FIGURE 7A shows a conditioned avoidance response (CAR) in mice trained in a CAR model of psychosis as compared to vehicle control
  • FIGURE 7B illustrates that Compound 12-132 of the present invention (as identified in Table 1 of Example 12) significantly reduces hyperactivity of mice in the PCP-induced model of psychosis as compared to vehicle control (FIGURE
  • FIGURES 9A and 9B illustrate that Compound 12-134 of the present invention (as identified in Table 1 of Example 12) significantly reduces hyperactivity of mice in the PCP-induced model of psychosis, in dose-dependent fashion, as compared to vehicle control (FIGURE 9A) and significantly reduces a conditioned avoidance response (CAR) in mice trained in a CAR model of psychosis, in dose-dependent fashion, as compared to vehicle control (FIGURE 9B).
  • CAR conditioned avoidance response
  • FIGURES 1OA and 1OB illustrate that Compound 12-115 of the present invention (as identified in Table 1 of Example 12) significantly reduces hyperactivity of mice in the PCP-induced model of psychosis, in a dose-dependent fashion, as compared to vehicle control (FIGURE 10A) and significantly reduces a conditioned avoidance response (CAR) in mice trained in a CAR model of psychosis as compared to vehicle control (FIGURE 10B).
  • Compound 12-115 of the present invention as identified in Table 1 of Example 12 significantly reduces hyperactivity of mice in the PCP-induced model of psychosis, in a dose-dependent fashion, as compared to vehicle control (FIGURE 10A) and significantly reduces a conditioned avoidance response (CAR) in mice trained in a CAR model of psychosis as compared to vehicle control (FIGURE 10B).
  • FIGURES HA and HB illustrate that Compound 12-140 of the present invention (as identified in Table 1 of Example 12) significantly reduces hyperactivity of mice in the PCP-induced model of psychosis, in a dose-dependent fashion, as compared to vehicle control (FIGURE HA) and significantly reduces a conditioned avoidance response (CAR) in mice trained in a CAR model of psychosis, in a dose-dependent fashion, as compared to vehicle control (FIGURE HB).
  • Compound 12-140 of the present invention as identified in Table 1 of Example 12 significantly reduces hyperactivity of mice in the PCP-induced model of psychosis, in a dose-dependent fashion, as compared to vehicle control (FIGURE HA) and significantly reduces a conditioned avoidance response (CAR) in mice trained in a CAR model of psychosis, in a dose-dependent fashion, as compared to vehicle control (FIGURE HB).
  • FIGURES 12A and 12B illustrate that Compound 12-142 of the present invention (as identified in Table 1 of Example 12) significantly reduces hyperactivity of mice in the PCP-induced model of psychosis as compared to vehicle control (FIGURE
  • the present invention is directed generally to compounds useful as PDElO inhibitors, as well as to methods for their preparation and use, and to pharmaceutical compositions containing the same.
  • the PDElO inhibitors have the following structure
  • X is -O- or -S-;
  • Ri is Ci_ 6 alkyl, Ci_ 6 haloalkyl, Ci_ 6 aralkyl, aryl, -(CH 2 ) «O(CH 2 ) m CH 3 or -(CH 2 ) «N(CH 3 ) 2 ;
  • R 2 and R 3 are the same or different and independently substituted or unsubstituted heterocyclyl, or substituted or unsubstituted aryl;
  • R 4 and R 5 are the same or different and independently hydrogen, Ci_ 6 alkyl or Ci_ 6 haloalkyl; n is 1, 2, 3, 4, 5 or 6; and m is 0, 1, 2, 3, 4, 5 or 6.
  • the PDElO inhibitors have the following structure (IV):
  • Ri is hydrogen, Ci- ⁇ alkyl, Ci- ⁇ haloalkyl, Ci_ 6 aralkyl, aryl, -(CH 2 ) «O(CH 2 ) m CH 3 or -(CH 2 ) «N(CH 3 ) 2 ; R 2 is substituted or unsubstituted aryl;
  • R 3 is substituted or unsubstituted heterocyclyl, or substituted or unsubstituted aryl
  • R 4 and R 5 are the same or different and independently hydrogen, Ci_ 6 alkyl or Ci- ⁇ haloalkyl; n is 1, 2, 3, 4, 5 or 6; and m is O, 1, 2, 3, 4, 5 or 6.
  • Haldroxy or “hydroxy 1” refers to the -OH radical.
  • Niro refers to the -NO 2 radical.
  • Ci_6alkyl means a straight chain or branched, noncyclic or cyclic, unsaturated or saturated aliphatic hydrocarbon radical containing from 1 to 6 carbon atoms.
  • Representative saturated straight chain alkyls include methyl, ethyl, n-propyl, n- butyl, n-pentyl, n-hexyl, and the like; while saturated branched alkyls include isopropyl, sec-butyl, isobutyl, tert-hvXy ⁇ , isopentyl, and the like.
  • saturated cyclic alkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like; while unsaturated cyclic alkyls include cyclopentenyl and cyclohexenyl, and the like.
  • Unsaturated alkyls contain at least one double or triple bond between adjacent carbon atoms (referred to as an "alkenyl” or “alkynyl", respectively).
  • Representative straight chain and branched alkenyls include ethylenyl, propylenyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3 -methyl- 1-butenyl, 2-methyl-2-butenyl, 2,3- dimethyl-2-butenyl, and the like; while representative straight chain and branched alkynyls include acetylenyl, propynyl, 1-butynyl, 2- butynyl, 1-pentynyl, 2-pentynyl, 3- methyl-1-butynyl, and the like.
  • Ci_6alkylene or “Ci_6alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, which is saturated or unsaturated (i.e., contains one or more double and/or triple bonds), and having from one to six carbon atoms, e.g., methylene, ethylene, propylene, n-butylene, ethenylene, propenylene, n-butenylene, propynylene, n-butynylene, and the like.
  • the alkylene chain is attached to the rest of the molecule through a single or double bond and to the radical group through a single or double bond.
  • Ci_6alkoxy refers to a radical of the formula -ORa where Ra is an alkyl radical as defined above, for example, methoxy, ethoxy and the like.
  • Aryl means a hydrocarbon ring system radical comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring.
  • the aryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems.
  • Aryl radicals include, but are not limited to, aryl radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, ⁇ s-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene.
  • Ci_ 6 aralkyl means a radical of the formula -R t ,-R c where R b is an alkylene chain as defined above and R c is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl and the like.
  • Cycloalkyl or “carbocyclic ring” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, preferably having from three to ten carbon atoms, and which is saturated or unsaturated and attached to the rest of the molecule by a single bond.
  • Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Polycyclic radicals include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like.
  • Halo or “halogen” refers to bromo, chloro, fluoro or iodo.
  • Ci_ 6 haloalkyl refers to a Ci_ 6 alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1 ,2-difluoroethyl,
  • Heterocycle or “heterocyclyl” means a 4- to 7-membered monocyclic, or 7- to 10-membered bicyclic, heterocyclic ring which is either saturated, unsaturated or aromatic, and which contains from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized, including bicyclic rings in which any of the above heterocycles are fused to a benzene ring.
  • the heterocycle may be attached via any heteroatom or carbon atom.
  • An aromatic heterocycle is referred to herein as a "heteroaryl", and includes (but is not limited to) furyl, benzofuranyl, thiophenyl, benzothiophenyl, pyrrolyl, indolyl, isoindolyl, azaindolyl, pyridyl, quinolinyl, isoquinolinyl, oxazolyl, isooxazolyl, benzoxazolyl, pyrazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, oxadiazolyl, thiadiazolyl, benzisoxazolyl, triazolyl, tetrazolyl, indazolyl and quina
  • heterocycles also include morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, and the like.
  • heterocycles also include benzothiophen-2-yl, 2,3-dihydrobenzo-l,4-dioxin-6- yl, benzo-l,3-dioxol-5-yl and the like.
  • substituted as used herein (for example, in the context of a substituted heterocyclyl or substituted aryl) means that at least one hydrogen atom is replaced with a substituent.
  • R a and R b in this context may be the same or different and independently hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, aralkyl, heterocyclyl.
  • the foregoing substituents may be further substituted with one or more of the above substituents.
  • X is -O- and the compound has the following structure (II):
  • Ri is Ci_ 6 alkyl, Ci_ 6 haloalkyl, Ci_ 6 aralkyl, aryl, -(CH 2 ) «O(CH 2 ) m CH 3 or -(CH 2 ) «N(CH 3 ) 2 ;
  • R 2 is substituted or unsubtituted heterocyclyl, substituted phenyl, or substituted or unsubstituted naphthyl
  • R 3 is substituted or unsubstituted heterocyclyl, or substituted or unsubstituted aryl
  • R 4 and R 5 are the same or different and independently hydrogen, Ci_ 6 alkyl or Ci- ⁇ haloalkyl; n is 1, 2, 3, 4, 5 or 6; and m is O, 1, 2, 3, 4, 5 or 6.
  • R 4 and R5 are the same or different and independently hydrogen or C ⁇ alkyl (such as, for example, hydrogen), Ri is Ci_ 6 alkyl (such as, for example, methyl, ethyl or isopropyl), R 3 is substituted phenyl (such as, for example, 3,4,5-trimethoxyphenyl or 4-bromo-3,5- dimethoxyphenyl) and/or R 2 is substituted or unsubstituted phenyl (such as, for example, 4-morpholinophenyl or 4-(lH-pyrazol-l-yl)phenyl), substituted or unsubstituted naphthyl, or substituted or unsubstituted heteroaryl.
  • C ⁇ alkyl such as, for example, hydrogen
  • Ri is Ci_ 6 alkyl (such as, for example, methyl, ethyl or isopropyl)
  • R 3 is substituted phenyl (such as, for example, 3,4,5-trimethoxyphen
  • X is -S- and the compound has the following structure (III):
  • Ri is Ci_ 6 alkyl, Ci_ 6 haloalkyl, -(C ⁇ 2 ) « O(C ⁇ 2 ) m C ⁇ 3 or -(CH 2 ) ⁇ N(CHs) 2 ;
  • R 2 and R 3 are the same or different and independently substituted or unsubstituted heterocyclyl, or substituted or unsubstituted aryl; and R 4 and R 5 are the same or different and independently hydrogen,
  • Ci_ 6 alkyl or Ci_ 6 haloalkyl n is 1, 2, 3, 4, 5 or 6; and m is O, 1, 2, 3, 4, 5 or 6.
  • R 4 and R5 are the same or different and independently hydrogen or C ⁇ alkyl (such as, for example, hydrogen)
  • Ri is Ci_ 6 alkyl (such as, for example, methyl, ethyl or isopropyl)
  • R 3 is substituted phenyl (such as, for example, 3,4,5-trimethoxyphenyl or 4-bromo-3,5- dimethoxyphenyl) and/or R 2 is substituted or unsubstituted phenyl (such as, for example, 4-morpholinophenyl or 4-(lH-pyrazol-l-yl)phenyl), substituted or unsubstituted naphthyl, or substituted or unsubstituted heteroaryl.
  • Ri is hydrogen, Ci_ 6 alkyl, Ci_ 6 haloalkyl, Ci_ 6 aralkyl, aryl, -(CH 2 ) « O(CH 2 ) m CH 3 or -(CH 2 ) « N(CH 3 ) 2 ;
  • R 2 is
  • R 2a is -N(R 2 bR 2c ) or a heterocyclic ring containing at least one N ring atom
  • R 2 b and R 2c are the same or different and independently hydrogen, Ci- ⁇ alkyl, Ci- ⁇ haloalkyl, Ci_ 6 aralkyl or aryl;
  • R 3a is -Ci_6alkoxy
  • R 3 b is halogen
  • R 3c is -Ci_ 6 alkoxy
  • R 4 and R 5 are the same or different and independently hydrogen, Ci_ 6 alkyl or Ci_ 6 haloalkyl; n is 1, 2, 3, 4, 5 or 6; and m is O, 1, 2, 3, 4, 5 or 6.
  • Ri is hydrogen, Ci_ 6 alkyl, Ci_ 6 haloalkyl, Ci_ 6 aralkyl, aryl, -(CH 2 ) « O(CH 2 ) m CH 3 or -(CH 2 ) « N(CH 3 ) 2 ;
  • R 2a is -N(R2bR2c) or a heterocyclic ring containing at least one N ring atom, provided that R 2a is not lH-tetrazol-1-yl, and
  • R 2b and R 2c are the same or different and independently hydrogen, Ci_ 6 alkyl, Ci_ 6 haloalkyl, Ci_ 6 aralkyl or aryl;
  • R 3a is -Ci_ 6 alkoxy, and R 3c is -Ci_6alkoxy; R 4 and R 5 are the same or different and independently hydrogen,
  • Ci_ 6 alkyl or Ci- ⁇ haloalkyl is 1, 2, 3, 4, 5 or 6; and m is O, 1, 2, 3, 4, 5 or 6.
  • R 4 and R5 are hydrogen or d_ 6 alkyl (such as, for example, hydrogen)
  • Ri is hydrogen or d_ 6 alkyl (such as, for example, methyl, ethyl, isopropyl or cyclopropyl)
  • R 3 is substituted phenyl (such as, for example, 3,4,5-trimethoxyphenyl or 4-bromo-3,5-dimethoxyphenyl) and/or R 2 is substituted or unsubstituted phenyl (such as, for example, 4-morpholinophenyl or 4-(lH-pyrazol-l-yl)phenyl) or substituted or unsubstituted naphthyl.
  • the compounds of the present invention may be prepared by known organic synthesis techniques, including the methods described in more detail in the Examples, or in some instances may be obtained from commercially available sources.
  • the compounds of structures (I) and (IV) above may be made by the following reaction schemes, wherein all substituents are as defined above unless indicated otherwise.
  • Compounds of formula 1 can be obtained commercially or synthesized through standard literature methods. Compounds of formula 1 can be reacted with a variety of alcohols using the method disclosed in U.S. Patent No. 7,129,238 (which is incorporated herein by reference in its entirety) to provide compounds of formula 2. Compounds of formula 2 can be heated with a variety of alcohols under acidic conditions to provide compounds of formula 3. Compounds of formula 3 can then be heated to reflux in the presence of hydrazine hydrate in an alcoholic solvent to provide compounds of formula 4. Compounds of formula 4 can be reacted with aldehydes or ketones of formula 5 to provide compounds of structure (II).
  • Compounds of formula 1 can be obtained commercially or synthesized through standard literature methods. Compounds of formula 1 can be reacted with a variety of halogenating reagents such as NCS to provide compounds of formula 2.
  • Compounds of formula 2 can be reacted with aromatic compounds under Friedel-Crafts conditions to provide compounds of formula 3.
  • Compounds of formula 3 can then be heated to reflux in the presence of hydrazine hydrate in an alcoholic solvent to provide compounds of formula 4.
  • Compounds of formula 4 can be reacted with aldehydes or ketones of formula 5 to provide compounds of structure (III).
  • Compounds of formula 1 can be obtained commercially or synthesized through standard literature methods. Compounds of formula 1 can be reacted with a variety of alcohols under acidic conditions to provide compounds of formula 2. Compounds of formula 2 can be treated with a variety of bases and alkylating reagents to provide compounds of formula 3. Compounds of formula 3 can then be heated to reflux in the presence of hydrazine hydrate in an alcoholic solvent to provide compounds of formula 4. Compounds of formula 4 can be reacted with aldehydes or ketones of formula 5 to provide compounds of structure (IV).
  • the compounds of the present invention may generally be utilized as the free acid or free base. Alternatively, the compounds of this invention may be used in the form of acid or base addition salts. Acid addition salts of the free amino compounds of the present invention may be prepared by methods well known in the art, and may be formed from organic and inorganic acids. Suitable organic acids include maleic, fumaric, benzoic, ascorbic, succinic, methanesulfonic, acetic, trifluoroacetic, oxalic, propionic, tartaric, salicylic, citric, gluconic, lactic, mandelic, cinnamic, aspartic, stearic, palmitic, glycolic, glutamic, and benzenesulfonic acids.
  • Suitable inorganic acids include hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acids.
  • Base addition salts included those salts that form with the carboxylate anion and include salts formed with organic and inorganic cations such as those chosen from the alkali and alkaline earth metals (for example, lithium, sodium, potassium, magnesium, barium and calcium), as well as the ammonium ion and substituted derivatives thereof (for example, dibenzylammonium, benzylammonium, 2-hydroxyethylammonium, and the like).
  • the term "pharmaceutically acceptable salt" of structures (I) through (IV) is intended to encompass any and all acceptable salt forms.
  • prodrugs are also included within the context of this invention.
  • Prodrugs are any covalently bonded carriers that release a compound of structures (I) through (IV) in vivo when such prodrug is administered to a patient.
  • Prodrugs are generally prepared by modifying functional groups in a way such that the modification is cleaved, either by routine manipulation or in vivo, yielding the parent compound.
  • Prodrugs include, for example, compounds of this invention wherein hydroxy, amine or sulfhydryl groups are bonded to any group that, when administered to a patient, cleaves to form the hydroxy, amine or sulfhydryl groups.
  • prodrugs include (but are not limited to) acetate, formate and benzoate derivatives of alcohol and amine functional groups of the compounds of structures (I) through (IV).
  • esters may be employed, such as methyl esters, ethyl esters, and the like.
  • prodrugs having the following structures (I-A), (I-B), (IV-A) and (IV-B) are included within the scope of this invention:
  • Enolic prodrugs of structure (I-A) and (IV-A) may be prepared by treating a compound of structure (I) or structure (IV), respectively, with a base, such as triethylamine, in a solvent, such as dichloromethane, followed by the addition of an electrophile, such as acetyl chloride.
  • a base such as triethylamine
  • a solvent such as dichloromethane
  • N-acylated prodrugs of structure (I-B) and (IV-B) may be prepared via thermal rearrangement by heating a prodrug of structure (I-A) or (IV-A), respectively, in a solvent, such as toluene.
  • a solvent such as toluene.
  • the compounds of structures (I) through (IV) may have chiral centers and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers. All such isomeric forms are included within the present invention, including mixtures thereof. Furthermore, some of the crystalline forms of the compounds of structures (I) through (IV) may exist as polymorphs, which are included in the present invention. In addition, some of the compounds of structures (I) through (IV) may also form solvates with water or other organic solvents. Such solvates are similarly included within the scope of this invention.
  • compositions containing one or more compounds of structures (I) through (IV) are disclosed.
  • the compounds of the present invention may be formulated as pharmaceutical compositions.
  • Pharmaceutical compositions of the present invention comprise one or more compounds of the present invention and a pharmaceutically acceptable carrier and/or diluent.
  • the PDElO inhibitor is present in the composition in an amount which is effective to treat a particular disorder—that is, in an amount sufficient to achieve desired PDElO inhibition, and preferably with acceptable toxicity to the warm-blooded animal.
  • the pharmaceutical compositions of the present invention may include a PDElO inhibitor in an amount from 0.1 mg to 250 mg per dosage depending upon the route of administration, and more typically from 1 mg to 60 mg. Appropriate concentrations and dosages can be readily determined by one skilled in the art.
  • a typical daily dosage might range from about 1 ⁇ g/kg to 100 mg/kg, preferably 0.01-100 mg/kg, more preferably 0.1-70 mg/kg, depending on the type and severity of the disease whether, for example, by one or more separate administrations. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of disease symptoms occurs.
  • other dosage regimens may be useful. The progress of this therapy can be monitored by standard techniques and assays.
  • the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
  • compositions formulated as liquid solutions include saline and sterile water, and may optionally include antioxidants, buffers, bacteriostats and other common additives.
  • the compositions can also be formulated as pills, capsules, granules, or tablets which contain, in addition to a PDElO inhibitor, diluents, dispersing and surface active agents, binders, and lubricants.
  • PDElO inhibitor one skilled in this art may further formulate the PDElO inhibitor in an appropriate manner, and in accordance with accepted practices, such as those disclosed in Remington's Pharmaceutical Sciences, Gennaro, Ed., Mack Publishing Co., Easton, PA 1990.
  • the present invention provides a method for treating diseases such as (but not limited to) psychotic disorders, anxiety disorders, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, bipolar disorders, post-traumatic stress disorders, drug-induced psychosis, panic disorders, obsessive-compulsive disorders, attention-deficit disorders, disruptive behavior disorders, autism, depression, dementia, cognitive disorders, epilepsy, insomnias and multiple sclerosis as discussed above.
  • diseases such as (but not limited to) psychotic disorders, anxiety disorders, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia
  • Such methods include administering of a compound of the present invention to a warm-blooded animal in an amount sufficient to treat the condition.
  • "treat” includes prophylactic administration.
  • Such methods include systemic administration of a PDElO inhibitor of this invention, preferably in the form of a pharmaceutical composition as discussed above.
  • systemic administration includes oral and parenteral methods of administration, including subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraarticular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, intravenous, intradermal, inhalational, transdermal, transmucosal, and rectal administration.
  • suitable pharmaceutical compositions of PDElO inhibitors include powders, granules, pills, tablets, and capsules as well as liquids, syrups, suspensions, and emulsions. These compositions may also include flavorants, preservatives, suspending, thickening and emulsifying agents, and other pharmaceutically acceptable additives and excipients.
  • the compounds of the present invention can be prepared in aqueous injection solutions which may contain, in addition to the PDElO inhibitor, buffers, antioxidants, bacteriostats, and other additives and excipients commonly employed in such solutions.
  • compositions of the present invention may be carried in a delivery system to provide for sustained release or enhanced uptake or activity of the therapeutic compound, such as a liposomal or hydrogel system for injection, a microparticle, nanopartical or micelle system for oral or parenteral delivery, or a staged capsule system for oral delivery.
  • a delivery system to provide for sustained release or enhanced uptake or activity of the therapeutic compound, such as a liposomal or hydrogel system for injection, a microparticle, nanopartical or micelle system for oral or parenteral delivery, or a staged capsule system for oral delivery.
  • compounds of structures (I) through (IV) are expected to avoid or reduce metabolic side effects associated with conventional antipsychotics, in particular the incidence of therapeutically induced obesity.
  • conventional antipsychotics in particular the incidence of therapeutically induced obesity.
  • olanzapine Zyprexa®
  • the most widely prescribed medication to treat schizophrenia, and related atypical antipsychotics is associated with significant metabolic side effects including obesity and associated conditions such as diabetes.
  • subchronic treatment with olanzapine stimulates food intake and increases body weight, consistent with human situations.
  • olanzapine acutely lowers blood leptin levels.
  • Leptin is a satiety hormone produced from adipose tissues, and decrease of leptin level stimulates appetite.
  • olanzapine could stimulate food intake at least partly by reducing leptin levels.
  • Acute administration of olanzapine also changes the animal's response in glucose and insulin levels in glucose tolerance tests, which may also be directly linked to olanzapine's effect in food intake and body weight gain.
  • Examination of the acute effect of PDElO inhibitors of the present invention on metabolism, such as leptin, insulin and glucose changes during a metabolic challenge in standard animal models, as well as the chronic effect of PDElO inhibitors of the present invention in food intake, body weight and energy homeostasis, in comparison with olanzapine should provide evidence to the pharmaceutical advantage of PDElO inhibitors as antipsychotics in terms of less side- effect concerns.
  • compositions of the present invention may be administered in combination with one or more additional therapeutic agents, in combination or by concurrent or sequential administration.
  • additional agents i.e., adjuvants
  • Compounds of this invention may be assayed to determine their IC50 values by a modification of the two-step method of Thompson and Appleman (Biochemistry 10; 311-316; 1971).
  • cAMP is spiked with ( 3 H)cAMP and incubated with PDElO and various concentrations of a compound of structure (I). After the appropriate incubation time, the reaction is terminated by heating. The mixture is then subjected to treatment with snake venom phosphatase. The phosphatase hydrolyzes any AMP in the mixture, but leaves unreacted cAMP intact. Thus, by separating cAMP from the mixture and determining its concentration (by radiography), the percent of inhibition can be determined. IC50 values can be calculated by performing the experiment at several concentrations using standard graphical means. A detailed description of the actual technique used for IC50 assays as set forth in following Examples. To this end, PDElO inhibitors of the invention have an IC 50 of lOO ⁇ M or less, generally less than 10 ⁇ M, and typically less than 1 ⁇ M.
  • Methyl 2-chloro-2-(methylthio)acetate can be synthesized according to literature procedures (Boehme, H.; Krack, W.; Justus Liebigs Annalen der Chemie; 1977; 51-60. Iwama, Tetsuo; Harutoshi, Matsumoto; Tadashi, Kataoka; Journal of the Chemical Society, Perkin Transactions 1 : Organic and Bio-Organic Chemistry (1972- 1999); 1997; 835-844).
  • Ethyl 2-(4-(dimethylamino)phenyl)-2-methoxyacetate was synthesized from ethyl 2-(4-(dimethylamino)phenyl)-2-hydroxyacetate according to the method used for the preparation of Example 6.
  • the product, isolated after extractive workup, was an orange oil (0.675 g, 65% yield) and was used without further purification.
  • the phosphodiesterase (PDE) assay was performed using recombinant human PDE 1A3, 2 A3, 3 catalytic region, 4 catalytic region, 5 catalytic region, 7 A, 8 A, 9A2, 10Al and 1 IAl enzymes expressed in a baculoviral system using Sf9 cells.
  • PDE activity was measured using a modification of the two-step method of Thompson and Appleman described above which was adapted for 96 well plate format.
  • the effect of the PDE inhibitors was determined by assaying a fixed amount of the enzyme in the presence of test compound concentrations and a substrate concentration below that of the Km, so that Ki equals IC 50 .
  • the final assay volume was 110 ⁇ l with assay buffer (1OmM MgCl 2 ; 4OmM Tris.HCl; pH 7.4). Reactions were initiated with enzyme and incubated with ( 3 H) -substrate and substance for 20 minutes at 30 0 C. The reaction was terminated by denaturing the enzyme (heating the reaction to 70 0 C for 2 minutes). The reaction was then cooled at 4 0 C for 10 minutes before the addition of snake venom (Crotalus atrox, 0.2 mg/ml) for 10 minutes at 30 0 C, thus allowing non-specific hydrolysis of the tritiated substrate.
  • assay buffer 1OmM MgCl 2 ; 4OmM Tris.HCl; pH 7.4
  • Purified PDElO was diluted and stored in 25 mM Tris-Cl (pH 8.0)/100 mM NaCl/0.05% Tween 20/50% glycerol/3 mM DTT. Assays contained (final concentrations): 50 mM Tris-Cl (pH 7.5)/8.3 mM MgCl 2 A .7 mM EGTA/0.5 mg/ml BSA/5% DMSO and 2 ng PDElO in a final volume of 0.1 mL. Inhibition was evaluated at 8 concentrations in duplicate. Reactions were initiated by addition of enzyme and were terminated after 20 minutes at 30 0 C by the addition of 50 ⁇ l of SPA beads containing Zn ++ .
  • results were fitted to a four parameter logistic model using Excel Solver ® . Further, the inhibition of other PDE enzymes by the PDElO inhibitors was evaluated under the same conditions described above for PDElO except the amount of enzyme added was optimized for each PDE. Fractional inhibition was evaluated at four concentrations (0.1, 1, 10, and 100 ⁇ M). In cases where inhibition at the highest concentration was less than 50%, the lower limit value in the logistic model was fixed to 0% activity.
  • compounds of this invention are PDElO inhibitors with an IC 50 of lOO ⁇ M or less, generally less than 10 ⁇ M, and typically less than 1 ⁇ M.
  • Schizophrenia has been associated with dysfunctions of dopaminergic, glutamatergic and serotonergic neurotransmission.
  • Psychostimulant drugs in these three classes dopaminergic agonists (such as amphetamine and apomorphine), glutamatergic antagonists (such as PCP and ketamine), and serotonergic agonists (such as LSD and MDMA), all induce psychotomimetic states (e.g., hyperactivity and disruption of prepulse inhibition) in animals that closely resemble schizophrenia symptoms in humans.
  • Known antipsychotic drugs including both typical antipsychotics (e.g., haloperidol) and atypical antipsychotics (e.g., olanzapine), reverse such psychotomimetic states in animals.
  • Examples 14-15 described below evaluate representative compounds of the present invention in animal behavioral models to compare the resulting effect to that of known antipsychotics.
  • Methods used in the Examples 14-15 are as follows.
  • Psychostimulant-induced hyperactivity is measured by injecting animals with PCP and monitoring the animals' activity levels in the VersaMax chambers (Accuscan Instruments, Columbus, OH) measuring 40 x 40 cm.
  • Locomotor activity is detected by photobeam breaks as the animal crosses each beam. The animal is placed in the center of the field and left undisturbed for a period of time (20 min to 2 hr) to measure its spontaneous activity in a novel environment.
  • Measurements used to assess locomotor activity include: horizontal activity, total distance traveled, vertical activity (rearing events - animal raises up on hindlimbs), rotation, stereotypy, and distance traveled in the center compared to total distance traveled (center: total distance ratio).
  • the NMDA antagonist PCP induces psychosis-like conditions manifested as hyperactivity and increased stereotypic behavior.
  • Known antipsychotics are able to reverse psychostimulant-induced hyperactivity and increased stereotypy.
  • Conditioned avoidance response is a behavioral test to evaluate antipsychotic effect of a test compound. It utilizes a shuttle box (Med Associates, St. Albans, VT) with two equal chambers separated by a retractable door. Each chamber is fitted with metal grid floor that is capable of delivering electric shocks independently.
  • a computer program is used to implement the testing paradigm as well as record the animal's movement between the two chambers through infrared beam sensors. The testing paradigm is as the follows. A mouse is placed into one chamber. A light (conditioned stimulus, CS) comes on.
  • the animals are trained in such paradigm for 15-20 days, during which the average percentage of avoidance responses will improve to 60-80%. This indicates that animals have learned to avoid the onset of footshocks by moving to the opposite chamber upon activation of the CS (light). These trained animals are then used for compound testing using the same paradigm.
  • Known antipsychotics have been found to inhibit the conditioned avoidance response, and the ability of new compounds to inhibit this response is thought to be predictive of antipsychotic effect in humans.
  • Compounds 12-63, 12-55 and 12-60 of the present invention were evaluated for the ability to significantly and substantially reduce PCP-induced hyperactivity.
  • C57BL/6 male mice were injected with either compound (10 mg/kg) or vehicle via i.p.
  • the mice were injected with PCP (5 mg/kg) via i.p.
  • the mice were placed in the activity chambers 10 minutes after PCP injection and their locomotor activities were monitored by infrared beam breaks for 20 min.
  • Example 12 was evaluated for the ability to reduce Conditioned Avoidance Response after oral dosing, as shown in FIGURE 4.
  • C57BL/6 male mice were trained in the CAR paradigm to predict and avoid the noxious stimulus, reaching a plateau of approximately 20-25 avoidance responses per 30 trials ("training plateau") each day.
  • the mice were then injected with either compound or vehicle via i.p., and 20 minutes later they were tested for 30 trials in the CAR paradigm.
  • Vehicle treatment and compound treatment were given to the same animals on alternating days, and the effect of compound in reducing avoidance response was analyzed through within-subject comparison (paired t-test). Vehicle exposure (“vehicle”) does not alter the avoidance response of these trained animals.
  • Compound 12-63 (as identified in Table 1 of Example 12) was found to reduce PCP-induced hyperactivity, as shown in FIGURE 5 A.
  • C57BL/6 male mice were administered either compound or vehicle via oral gavage. Fifteen minutes later, the mice were injected with PCP (5 mg/kg) via the i.p. route. The mice were placed in activity chambers 10 minutes after PCP injection, and their locomotor activity in the horizontal dimension was monitored by infrared beam breaks for 20 min (5 consecutive 4-minute intervals (INT) as indicated).
  • INT 4-minute intervals
  • Compound 12-63 (as identified in Table 1 of Example 12) was found to reduce Conditioned Avoidance Responses (CAR), as shown in FIGURE 5B.
  • CAR Conditioned Avoidance Responses
  • CAR Conditioned Avoidance Responses
  • Compound 12-104 (as identified in Table 1 of Example 12) was found to reduce PCP-induced hyperactivity, as shown in FIGURE 6 A.
  • C57BL/6 male mice were administered either compound or vehicle via oral gavage. Twenty- five minutes later, the mice were injected with PCP (5 mg/kg) via the i.p. route. The mice were placed in activity chambers 10 minutes after PCP injection and their locomotor activity in the horizontal dimension was monitored by infrared beam breaks for 20 min (5 consecutive
  • Example 19 Reduction of Conditioned Avoidance Response by Compound 12-104 Compound 12-104 (as identified in Table 1 of Example 12) was found to reduce Conditioned Avoidance Responses (CAR), as shown in FIGURE 6B.
  • CAR Conditioned Avoidance Responses
  • CAR Conditioned Avoidance Responses
  • Example 21 Reduction of Conditioned Avoidance Response by Compound 12-114
  • Compound 12-114 (as identified in Table 1 of Example 12) was found to reduce Conditioned Avoidance Responses (CAR), as shown in FIGURE 7B.
  • CAR Conditioned Avoidance Responses
  • C57BL/6 male mice were trained in the CAR paradigm to predict and avoid the noxious stimulus (foot shock), reaching a plateau of approximately 25 avoidance responses per 30 trials each day.
  • the mice were then given either vehicle (15 minutes prior to testing) or compound (25 minutes prior to testing) via oral gavage, and then were tested for 30 trials in the CAR paradigm.
  • Vehicle treatment and compound treatment were given to the same animals on alternating days, and the effect of compound in reducing avoidance response was analyzed through within- subject comparison (paired t-test).
  • Compound 12-132 (as identified in Table 1 of Example 12) was found to reduce Conditioned Avoidance Responses (CAR), as shown in FIGURE 8B.
  • CAR Conditioned Avoidance Responses
  • CAR Conditioned Avoidance Responses
  • C57BL/6 male mice were trained in the CAR paradigm to predict and avoid the noxious stimulus (foot shock), reaching a plateau of approximately 25 avoidance responses per 30 trials ("training plateau”).
  • the mice were then given either vehicle (15 minutes prior to testing) or compound (25 minutes prior to testing) via oral gavage, and were then tested for 30 trials in the CAR paradigm.
  • Vehicle treatment and compound treatment were given to the same animals on alternating days, and the effect of compound in reducing avoidance response was analyzed through within- subject comparison (paired t-test). Vehicle exposure (“vehicle”) does not alter the avoidance response of these trained animals.
  • Compound 12-134 (as identified in Table 1 of Example 12) was found to reduce PCP-induced hyperactivity, as shown in FIGURE 9 A.
  • C57BL/6 male mice were administered either compound or vehicle via oral gavage. Twenty- five minutes later, the mice were injected with PCP (5 mg/kg) via the i.p. route. The mice were placed in the activity chambers 10 minutes after PCP injection and their locomotor activity in the horizontal dimension was monitored by infrared beam breaks for 20 min (5 consecutive 4-minute intervals (INT) as indicated).
  • Example 25 Reduction of Conditioned Avoidance Response by Compound 12-134 was found to reduce Conditioned Avoidance Responses (CAR), as shown in FIGURE 9B.
  • CAR Conditioned Avoidance Responses
  • CAR Conditioned Avoidance Responses
  • Compound 12-115 (as identified in Table 1 of Example 12) was found to reduce PCP-induced hyperactivity, as shown in FIGURE 1OA.
  • C57BL/6 male mice were administered either compound or vehicle via oral gavage. Twenty-five minutes later, the mice were injected with PCP (5 mg/kg) via the i.p. route. The mice were placed in the activity chambers 10 minutes after injection and their locomotor activity in the horizontal dimension was monitored by infrared beam breaks for 20 min (5 consecutive 4-minute intervals as indicated).
  • FIGURE 1OA shows that Compound 12-
  • Compound 12-115 (as identified in Table 1 of Example 12) was found to reduce Conditioned Avoidance Responses (CAR), as shown in FIGURE 1OB.
  • CAR Conditioned Avoidance Responses
  • CAR Conditioned Avoidance Responses
  • Compound 12-140 (as identified in Table 1 of Example 12) was found to reduce PCP-induced hyperactivity, as shown in FIGURE HA.
  • C57BL/6 male mice were administered either compound or vehicle via oral gavage. Twenty-five minutes later, the mice were injected with PCP (5 mg/kg) via the i.p. route. The mice were placed in the activity chambers 10 minutes after PCP injection and their locomotor activity in the horizontal dimension was monitored by infrared beam breaks for 20 min
  • FIGURE HA shows that
  • Compound 12-140 (as identified in Table 1 of Example 12) was found to reduce Conditioned Avoidance Responses (CAR), as shown in FIGURE HB.
  • CAR Conditioned Avoidance Responses
  • CAR Conditioned Avoidance Responses
  • Compound 12-142 (as identified in Table 1 of Example 12) was found to reduce PCP-induced hyperactivity, as shown in FIGURE 12A.
  • C57BL/6 male mice were administered either compound or vehicle via oral gavage. Twenty-five minutes later, the mice were injected with PCP (5 mg/kg) via the i.p. route. The mice were placed in the activity chambers 10 minutes after PCP injection and their locomotor activity in the horizontal dimension was monitored by infrared beam breaks for 20 min (5 consecutive 4-minute intervals (INT) as indicated).
  • Example 31 Reduction of Conditioned Avoidance Response by Compound 12-142
  • Compound 12-142 (as identified in Table 1 of Example 12) was found to reduce Conditioned Avoidance Responses (CAR), as shown in FIGURE HB.
  • CAR Conditioned Avoidance Responses
  • CAR Conditioned Avoidance Responses
  • FIGURE HB C57BL/6 male mice were trained in the CAR paradigm to predict and avoid the noxious stimulus (foot shock), reaching a plateau of approximately 25 avoidance responses per 30 trials each day. The mice were then given either vehicle (15 minutes prior to testing) or compound (25 minutes prior to testing) via oral gavage, and were tested for 30 trials in the CAR paradigm. Vehicle treatment and compound treatment were given to the same animals on alternating days, and the effect of compound in reducing avoidance response was analyzed through within-subject comparison (paired t-test). Vehicle exposure (“vehicle”) does not alter the avoidance response of these trained animals.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PCT/US2009/052754 2008-08-05 2009-08-04 Pde10 inhibitors and related compositions and methods Ceased WO2010017236A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES09805466.1T ES2654617T3 (es) 2008-08-05 2009-08-04 Inhibidores de PDE10 y composiciones y procedimientos relacionados
NZ590951A NZ590951A (en) 2008-08-05 2009-08-04 Cyclic nucleotide phosphodiesterases PDE10 inhibitors for treating neurological disorders
EP09805466.1A EP2310016B1 (en) 2008-08-05 2009-08-04 Pde10 inhibitors and related compositions and methods
JP2011522195A JP5759893B2 (ja) 2008-08-05 2009-08-04 Ｐｄｅ１０阻害剤ならびに関連する組成物および方法
AU2009279756A AU2009279756B2 (en) 2008-08-05 2009-08-04 PDE10 inhibitors and related compositions and methods
CA2733378A CA2733378C (en) 2008-08-05 2009-08-04 Pde10 inhibitors and related compositions and methods
CN200980134364.6A CN102143752B (zh) 2008-08-05 2009-08-04 Pde10抑制剂以及相关组合物和方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8640608P 2008-08-05 2008-08-05
US61/086,406 2008-08-05
US11808808P 2008-11-26 2008-11-26
US61/118,088 2008-11-26
US21831109P 2009-06-18 2009-06-18
US61/218,311 2009-06-18

Publications (1)

Publication Number Publication Date
WO2010017236A1 true WO2010017236A1 (en) 2010-02-11

Family

ID=41653504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/052754 Ceased WO2010017236A1 (en) 2008-08-05 2009-08-04 Pde10 inhibitors and related compositions and methods

Country Status (9)

Country Link
US (3) US8377930B2 (https=)
EP (1) EP2310016B1 (https=)
JP (1) JP5759893B2 (https=)
CN (1) CN102143752B (https=)
AU (1) AU2009279756B2 (https=)
CA (1) CA2733378C (https=)
ES (1) ES2654617T3 (https=)
NZ (1) NZ590951A (https=)
WO (1) WO2010017236A1 (https=)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2011112828A1 (en) 2010-03-12 2011-09-15 Omeros Corporation Pde10 inhibitors and related compositions and methods
WO2012112946A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US8377930B2 (en) 2008-08-05 2013-02-19 Omeros Corporation PDE10 inhibitors and related compositions and methods
JP2013095743A (ja) * 2011-11-07 2013-05-20 Akira Nakagawara 抗癌剤
JP2013536181A (ja) * 2010-08-02 2013-09-19 エフ．ホフマン−ラ ロシュ アーゲー 非定型抗精神病薬及びｔａａｒ１アゴニストを含む組合せ
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US8765760B2 (en) 2011-01-11 2014-07-01 Sunovion Pharmaceuticals, Inc. [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US9493447B2 (en) 2014-04-28 2016-11-15 Omeros Corporation Optically active PDE10 inhibitor
US9650368B2 (en) 2014-04-28 2017-05-16 Omeros Corporation Processes and intermediates for the preparation of a PDE10 inhibitor
US9879002B2 (en) 2015-04-24 2018-01-30 Omeros Corporation PDE10 inhibitors and related compositions and methods
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2936784B1 (fr) 2008-10-08 2010-10-08 Gaztransp Et Technigaz Cuve a membrane ondulee renforcee
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
US10927070B2 (en) 2016-06-09 2021-02-23 Cedars-Sinai Medical Center Compositions and methods for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
WO2008064342A2 (en) * 2006-11-21 2008-05-29 Omeros Corporation Pde10 inhibitors and related compositions and methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2615188B1 (fr) * 1987-05-14 1989-11-17 Meram Laboratoires Sa Derives d'hydrazine, procede d'obtention et compositions pharmaceutiques les contenant
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
MXPA02007252A (es) * 2000-01-28 2003-01-29 Rohm & Haas Compuestos farmaceuticos con propiedades mejoradas.
GB0223665D0 (en) 2002-10-10 2002-11-20 Syngenta Participations Ag Organic compounds
DE10346913A1 (de) * 2003-10-09 2005-05-04 Merck Patent Gmbh Acylhydrazonderivate
US9649295B2 (en) * 2004-01-21 2017-05-16 Cornell Research Foundation, Inc. Chemical inhibitors of soluble adenylyl cyclase (sAC)
AU2005218724A1 (en) 2004-03-08 2005-09-15 Merck Patent Gmbh Methods for altering insulin secretion
RU2006135653A (ru) 2004-03-11 2008-04-20 Мерк Патент ГмбХ (DE) Способы, препятствующие фиброзу
KR20070015148A (ko) 2004-03-11 2007-02-01 메르크 파텐트 게엠베하 혈청 및 글루코코르티코이드 유도가능한 키나아제의조절제의 용도를 포함하는 신경정신학적 장애를 치료하기위한 글루탐산 수용체의 조절 방법
WO2006121684A2 (en) 2005-05-06 2006-11-16 Boehringer Ingelheim International, Gmbh Acyl hydrazones for treating cardiovascular diseases
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009143178A2 (en) * 2008-05-20 2009-11-26 Omeros Corporation Pde10 inhibitors and related compositions and methods
AU2009279756B2 (en) 2008-08-05 2015-01-29 Omeros Corporation PDE10 inhibitors and related compositions and methods
KR101713453B1 (ko) 2010-03-12 2017-03-07 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
WO2008064342A2 (en) * 2006-11-21 2008-05-29 Omeros Corporation Pde10 inhibitors and related compositions and methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FUJISHIGE ET AL.: "Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both CAMP and cGMP (PDE10A", J BIOL CHEM, vol. 274, 1999, pages 18438 - 18445
LOUGHNEY ET AL.: "Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase", GENE, vol. 234, 1999, pages 109 - 117
LUGNIER, C.: "Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents", PHARMACOL THER., vol. 109, no. 3, March 2006 (2006-03-01), pages 366 - 98

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
US8278327B2 (en) 2006-11-21 2012-10-02 Omeros Corporation PDE10 inhibitors and related compositions and methods
US8377930B2 (en) 2008-08-05 2013-02-19 Omeros Corporation PDE10 inhibitors and related compositions and methods
US9783521B2 (en) 2008-08-05 2017-10-10 Omeros Corporation PDE10 inhibitors and related compositions and methods
CN102869355B (zh) * 2010-03-12 2015-07-08 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
AU2011224287B2 (en) * 2010-03-12 2015-03-26 Omeros Corporation PDE10 inhibitors and related compositions and methods
US8343970B2 (en) 2010-03-12 2013-01-01 Omeros Corporation PDE10 inhibitors and related compositions and methods
US10106516B2 (en) 2010-03-12 2018-10-23 Omeros Corporation PDE10 inhibitors and related compositions and methods
CN102869355A (zh) * 2010-03-12 2013-01-09 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
US8685975B2 (en) 2010-03-12 2014-04-01 Omeros Corporation PDE10 inhibitors and related compositions and methods
CN107445919A (zh) * 2010-03-12 2017-12-08 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
EP2544679A4 (en) * 2010-03-12 2014-05-14 Omeros Corp PDE10-HEMMER AND CORRESPONDING COMPOSITIONS AND METHODS
WO2011112828A1 (en) 2010-03-12 2011-09-15 Omeros Corporation Pde10 inhibitors and related compositions and methods
CN104710385B (zh) * 2010-03-12 2018-11-09 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
CN104710385A (zh) * 2010-03-12 2015-06-17 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
US9132136B2 (en) 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
JP2013536181A (ja) * 2010-08-02 2013-09-19 エフ．ホフマン−ラ ロシュ アーゲー 非定型抗精神病薬及びｔａａｒ１アゴニストを含む組合せ
JP2015145408A (ja) * 2010-08-02 2015-08-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 非定型抗精神病薬及びｔａａｒ１アゴニストを含む組合せ
US9249162B2 (en) 2011-01-11 2016-02-02 Sunovion Pharmaceuticals Inc. Substituted [1,2,4]triazolo[1,5-a]pyridines as PDE-10 inhibitors
US9856274B2 (en) 2011-01-11 2018-01-02 Sunovion Pharmaceuticals Inc. Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors
US10570156B2 (en) 2011-01-11 2020-02-25 Sunovion Pharmaceuticals Inc. Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors
US8765760B2 (en) 2011-01-11 2014-07-01 Sunovion Pharmaceuticals, Inc. [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
WO2012112946A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US8772316B2 (en) 2011-02-18 2014-07-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)
US9670181B2 (en) 2011-02-18 2017-06-06 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
JP2013095743A (ja) * 2011-11-07 2013-05-20 Akira Nakagawara 抗癌剤
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US9902710B2 (en) 2013-12-05 2018-02-27 Exonhit Therapeutics, Sa Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US9850238B2 (en) 2014-04-28 2017-12-26 Omeros Corporation Optically active PDE10 inhibitor
US9650368B2 (en) 2014-04-28 2017-05-16 Omeros Corporation Processes and intermediates for the preparation of a PDE10 inhibitor
US9493447B2 (en) 2014-04-28 2016-11-15 Omeros Corporation Optically active PDE10 inhibitor
US9879002B2 (en) 2015-04-24 2018-01-30 Omeros Corporation PDE10 inhibitors and related compositions and methods
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor

Also Published As

Publication number Publication date
US9783521B2 (en) 2017-10-10
AU2009279756B2 (en) 2015-01-29
CA2733378A1 (en) 2010-02-11
EP2310016A4 (en) 2011-09-21
NZ590951A (en) 2012-09-28
EP2310016B1 (en) 2017-10-04
CA2733378C (en) 2017-04-25
US20140038951A1 (en) 2014-02-06
CN102143752A (zh) 2011-08-03
US20100035872A1 (en) 2010-02-11
JP5759893B2 (ja) 2015-08-05
ES2654617T3 (es) 2018-02-14
JP2011530521A (ja) 2011-12-22
US8377930B2 (en) 2013-02-19
AU2009279756A1 (en) 2010-02-11
US20180118711A1 (en) 2018-05-03
EP2310016A1 (en) 2011-04-20
CN102143752B (zh) 2014-12-10

Similar Documents

Publication Publication Date Title
EP2310016B1 (en) Pde10 inhibitors and related compositions and methods
EP2544679B1 (en) Pde10 inhibitors and related compositions and methods
EP2083819B1 (en) Pde10 inhibitors and related compositions and methods
US20110021509A1 (en) Pde10 inhibitors and related compositions and methods
AU5793699A (en) Inhibitors of p38-alpha kinase
JP7062643B2 (ja) 化合物およびｐｄｅ４活性剤としてのそれらの使用
JP2018515594A (ja) トリアゾール誘導体およびｐｄｅ４活性化体としてその使用
KR20200030466A (ko) 7-하이드록시-4H-티에노[3,2-b]피리딘-5-온 유도체 및 그의 용도
HK1179883A (en) Pde10 inhibitors and related compositions and methods
HK1179883B (en) Pde10 inhibitors and related compositions and methods

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980134364.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09805466

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2733378

Country of ref document: CA

Ref document number: 2011522195

Country of ref document: JP

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2009805466

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 590951

Country of ref document: NZ

Ref document number: 2009805466

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009279756

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009279756

Country of ref document: AU

Date of ref document: 20090804

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1531/DELNP/2011

Country of ref document: IN